Bearing in mind that the TKI gefitinib has recently gained license approval for the treatment of first line NSCLC for patients harboring EGFR mutations [50], the search for similar biomarkers of response to anti-EGFR agents has become a priority in virtually all cancer types. Here, EGFR is linked to non-small cell lung carcinoma.